Astellas Venture Management

Astellas Venture Management investment thesis

Investment Scope Investment Targets We will make an investment in privately owned early-stage biotechnology company focused on therapeutics programs and platform technologies for drug discovery and development. Program stage should be in preclinical to be considered equity investment. Areas of Interest Our areas of interest are innovative therapeutic approach which is close to R&D strategy of Astellas Pharma (see: https://www.astellas.com/en/science/research-and-development ) and unprecedent treatment but that becomes realized in the near future. We prioritize companies with programs and technologies to fulfill unmet medical needs who have been wanting for. What AVM Provides The strength of AVM lies in our “Pharma View” based on our long-standing experiences in the pharmaceutical industry.

Astellas Venture Management team (5)

Partners and principals at Astellas Venture Management:

• Tadayoshi Hirata — sweet spot $1.5M
• Hiromichi Kimura — sweet spot $1.5M
• Satoshi Konagai — sweet spot $1.5M
• Kazunori Maruyama — sweet spot $1.5M
• Hikaru Saito — sweet spot $1.5M

Astellas Venture Management portfolio companies

Companies listed on Astellas Venture Management's public materials include: Team, Portfolio, News, New Portfolio since 2020, AVM_web-sm@astellas.com, Thank you for visiting the www.astellasventure.com, Continue, Cancel, Site Map, Cookies Policy, Legal Disclaimer.

Is Astellas Venture Management a fit for your round?

Upload your pitch deck and see whether anyone at Astellas Venture Management appears in your top matches.